Anti-Human GD3 ganglioside Recombinant Antibody (Ecromeximab) (CAT#: TAB-131)

Recombinant monoclonal antibody to GD3 ganglioside. Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Datasheet
  • MSDS
  • COA

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Chimeric (mouse/human)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, ICC and most other immunological methods.
  • CAS
  • 292819-64-8
  • Generic Name
  • Ecromeximab
  • MW
  • 14.5255 kDa
  • Related Disease
  • Malignant melanoma

Product Property

  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Target

  • Alternative Names
  • Ecromeximab;292819-64-8;KW2871;KW-2871;KM871;GD3 ganglioside

Related Resources

  • Biosimilar Overview
Please refer to Ecromeximab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Ecromeximab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Ecromeximab"

Afuco™ Anti-GD3 Ganglioside ADCC Recombinant Antibody (Ecromeximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to GD3 ganglioside. Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.

See other products for "GD3 ganglioside"

Single-domain Antibody

CAT Product Name Application Type
NAB-1058-VHH Recombinant Anti-Human GD3 ganglioside VHH Single Domain Antibody IHC, ICC, IP, ChiP, Neut Llama VHH

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-131 Afuco™ Anti-GD3 Ganglioside ADCC Recombinant Antibody (Ecromeximab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-131. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare